Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

British Business Bank leads Microbiotica's £36m Series C

1 min read
18:53UTC

The Cambridge microbiome company's first close puts its MB310 treatment on course for Phase 2 trials in ulcerative colitis.

TechnologyDeveloping
Key takeaway

Microbiotica's Series C is a rare round the British Business Bank led itself.

Microbiotica, a Cambridge microbiome company, said in mid-October that the British Business Bank led the first close of its £36m (about $48m) Series C⁠1. A first close is the point at which a round banks its initial commitments while leaving room for more investors to join.

The company said the money takes its MB310 treatment into Phase 2 trials for ulcerative colitis, a chronic inflammatory disease of the large bowel. Leading is unusual for the Bank. In August it took a £3.5m slice of Certain Energy's Series A as one investor among several.

Deep Analysis

In plain English

Microbiotica is a Cambridge company working on medicines made from carefully chosen gut bacteria. The idea is that the right bacteria can calm the inflammation behind some bowel diseases. Its treatment, MB310, is aimed at ulcerative colitis, a long-term condition that inflames the lining of the large bowel. The company is raising £36m to test it in patients, and the government-owned British Business Bank led the first part of that money.

Deep Analysis
Root Causes

Microbiome treatments use defined mixes of gut bacteria, so they sit between conventional drugs and biological products. Few specialist investors understand how to value them, which leaves room for a state-owned lead investor at Series C.

A first close also matters. It lets the company start Phase 2 planning while it raises the rest, but the £36m figure is the target for the round, not money already banked in full.

What could happen next?
  • Precedent

    The British Business Bank acting as lead investor gives a mid-sized Series C a priced anchor that later investors can follow.

First Reported In

Update #16 · Stryker agrees option to buy CMR Surgical

Startupmag· 22 Oct 2026
Read original →
Causes and effects
This Event
British Business Bank leads Microbiotica's £36m Series C
A state bank that usually follows private money led this round itself.
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.